Role of the endocannabinoid system in drug addiction

Jorge Manzanares\textsuperscript{a,b,e,*}, David Cabañero\textsuperscript{b,f}, Nagore Puente\textsuperscript{c,d,f}, María S. García-Gutiérrez\textsuperscript{a,f}, Pedro Grandes\textsuperscript{c,d,h,e,*}, Rafael Maldonado\textsuperscript{b,e,f,*}

\textsuperscript{a} Neurosciences Institute, Miguel Hernández University-CSIC, Avenue de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
\textsuperscript{b} Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Pompeu Fabra University, PRBB, C/ Doctor Aiguader 88, 08003 Barcelona, Spain
\textsuperscript{c} Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, E-48940 Leioa, Vizcaya, Spain
\textsuperscript{d} Ahuscarro Basque Center for Neuroscience, Science Park of the UPV/EHU, Leioa, Vizcaya, Spain
\textsuperscript{e} IMIM (Hospital del Mar, Medical Research Institute), Barcelona, Spain
\textsuperscript{f} Cooperative Health Research Thematic Network, Addictive Disorders Network, Health Institute Carlos III, MICINN and FEDER, Madrid, Spain

\textbf{A R T I C L E   I N F O}

Keywords:
Mesolimbic system
Nucleus accumbens
Prefrontal cortex
CB1 receptors
CB2 receptors
Rimonabant
CB2R allosteric modulators

\textbf{A B S T R A C T}

Drug addiction is a chronic relapsing disorder that produces a dramatic global health burden worldwide. Not effective treatment of drug addiction is currently available probably due to the difficulties to find an appropriate target to manage this complex disease raising the needs for further identification of novel therapeutic approaches. The endocannabinoid system has been found to play a crucial role in the neurobiological substrate underlying drug addiction. Endocannabinoids and cannabinoid receptors are widely expressed in the main areas of the mesocorticolimbic system that participate in the initiation and maintenance of drug consumption and in the development of compulsions and loss of behavioral control occurring during drug addiction. The identification of the important role played by CB1 cannabinoid receptors in drug addiction encouraged the possible used of an early commercialized CB1 receptor antagonist for treating drug addiction. However, the incidence of serious psychiatric adverse events leaded to the sudden withdrawal from the market of this CB1 antagonist and all the research programs developed by pharmaceutical companies to obtain new CB1 antagonists were stopped. Currently, new research strategies are under development to target the endocannabinoid system for drug addiction avoiding these side effects, which include allosteric negative modulators of CB1 receptors and compounds targeting CB2 receptors. Recent studies showing the potential role of CB2 receptors in the addictive properties of different drugs of abuse have open a promising research opportunity to develop novel possible therapeutic approaches.

1. Introduction

Drug addiction is a chronic relapsing disorder characterized by compulsive drug use and seeking in spite of negative consequences, loss of control over drug consumption and repeated relapse in drug use even after long periods of abstinence \cite{1}. It is estimated that 255 million people used illicit drugs in 2015, which translates into an annual prevalence of illicit drug use of 5.3%, being cannabis the most used \cite{2}. However, the global burden of disease and injury caused by licit drugs is even more dramatic. Indeed, tobacco kills more than 7 million people worldwide every year, being 12% of deaths of all people aged over 30 due to tobacco, whereas 3.3 million deaths every year result from harmful use of alcohol representing 5.9% of all deaths \cite{3}. In spite the enormous health burden worldwide of drug addiction, up to date not effective treatment is available probably due to the difficulties to find an appropriate target to manage this complex disease. Indeed, probably the most advance approach for treating drug addiction is the substitutive agonist treatment of opioid dependence \cite{4}. However, alcohol, nicotine, cannabis, psychostimulants and other kinds of addiction are fully devoid of an effective treatment. This lack of effective treatment underlines the needs of further research to better understand the neurobiological mechanisms involved in this disease in order to identify novel therapeutic targets and to develop novel compounds for treating drug addiction.

Acute administration of all the prototypical drugs of abuse including opioids, cannabinoids, psychostimulants, alcohol and nicotine, enhances the activity of the mesolimbic dopamine (DA) system \cite{5}. All these drugs increase DA release in the nucleus accumbens (NAc) shell through stimulation of DA neurons from the ventral tegmental area.

\textsuperscript{*} Corresponding authors at: Cooperative Health Research Thematic Network, Addictive Disorders Network, Health Institute Carlos III, MICINN and FEDER, Madrid, Spain.

\textit{E-mail addresses:} jmanzanares@goumh.umh.es (J. Manzanares), pedro.grandes@ehu.eus (P. Grandes), rafael.maldonado@upf.edu (R. Maldonado).

https://doi.org/10.1016/j.bcp.2018.09.013

Received 2 July 2018; Accepted 10 September 2018

0006-2952/ © 2018 Published by Elsevier Inc.
drug use and relapse that characterize the addicted disease. These alterations weaken the inhibitory control that cortical areas exert after repeated drug exposure. These changes are linked to neuroplastic down-regulation of DA signaling similar to that previously described in the reward circuit also occurs in the PFC and their associated circuits (VTA), and this neurochemical response has been related to the rewarding effects of drugs of abuse [6]. These rewarding effects produce a hedonic experience that is crucial for the initiation and maintenance of drug consumption [7]. However, repeated exposure to drugs of abuse produce important adaptive changes leading to an attenuated release of DA in the reward circuit that has been revealed in both animals [8] and humans [9]. This attenuated DA release renders the reward system less sensitive and the addict no longer experiences the same degree of euphoria when using the drug [10].

In addition, repeated drug exposure also produces adaptive changes in the circuitry of the extended amygdala resulting in enhanced reactivity to stress and the emergence of negative emotions [11]. This “antireward” system encompasses neurotransmitters involved in the stress response, including corticotropin-releasing factor and dynorphin, and becomes overactive in the addicted brain inducing important dysphoric effects when the drug is no longer present [12]. These emotional negative consequences also play a crucial role in the maintenance of drug consumption, leading to a compulsive intake not just to obtain reward, but also to alleviate the aversive state associated with drug withdrawal (See Table 1).

Table 1
Summary of results related with the involvement of CB2r on drug addiction.

<table>
<thead>
<tr>
<th>Evidences from pharmacological studies</th>
<th>Evidences from mice modify genetically</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cocaine</strong></td>
<td><strong>Transgenic CB2xP mice showed [139]:</strong></td>
</tr>
<tr>
<td>The CB2-agonist JWH133 (systematic and intra-NAc infusion) blocked cocaine-enhanced locomotion and inhibited intravenous cocaine self-administration in C57BL/6/J mice [145].</td>
<td>– less motor response to acute effects of cocaine,</td>
</tr>
<tr>
<td>CB2-agonist, AM630, reversed the cocaine-induced alterations in cell proliferation including neurogenic, apoptotic and gliosis processes in Wistar rats [216].</td>
<td>– less vulnerable to the motor sensitization induced by the repeated administration of cocaine.</td>
</tr>
<tr>
<td>CB2-antagonist, SR144528 reduced the reinstatement of cocaine consumption in Wistar rats [217].</td>
<td>– cocaine induces place-conditioned aversion.</td>
</tr>
<tr>
<td>The CB2-agonist AM630 failed to modify the acute and chronic locomotor effects induced by cocaine in Wistar rats [216].</td>
<td>– less acquisition of cocaine self-administration.</td>
</tr>
<tr>
<td>The blockade of CB2r did not modify contextual memories associated with cocaine seeking release in Wistar rats [217].</td>
<td><strong>CB2−/− mice showed:</strong> higher sensitivity to the cocaine-induced motor effects [215].</td>
</tr>
<tr>
<td>Increased CB2r gene expression in mouse brain preparations after repeated administration of cocaine [76].</td>
<td><strong>CB2−/− mice showed:</strong></td>
</tr>
<tr>
<td>Decreased CB2r protein expression in the prefrontal cortex of Sprague-Dawley rats during adolescence (PND33-39) after subchronic administration of cocaine [218].</td>
<td>– high vulnerability to the physiological effects of a single doses of ethanol [220].</td>
</tr>
<tr>
<td>Decreased CB2r immunoreactivity Lewis and Fischer 344 rats exposed to cocaine self-administration [219].</td>
<td>– increased voluntary ethanol consumption in the two-bottle paradigm [220].</td>
</tr>
<tr>
<td><strong>Alcohol</strong></td>
<td><strong>CB2−/− mice showed:</strong></td>
</tr>
<tr>
<td>The CB2-agonist beta-caryophyllene reduced ethanol conditioned place preference and ethanol consumption in C57BL/6/J mice [221].</td>
<td>– increased motivation to drink in the oral ethanol self-administration [220].</td>
</tr>
<tr>
<td>The cannabinoid CB2-agonist JWH015 increased alcohol consumption in C57/B6 mice previously exposed to chronic stress without [222].</td>
<td>– increased alcohol drinking in the intermittent forced drinking paradigm under group-housing conditions [223].</td>
</tr>
<tr>
<td>Downregulation of CB2r in the Amy [224] and striatum [225] of Wistar rats exposed to ethanol withdrawal.</td>
<td><strong>Nicotine</strong></td>
</tr>
<tr>
<td></td>
<td><strong>CB2−/− mice showed:</strong></td>
</tr>
<tr>
<td></td>
<td>– no nicotine conditioned place preference</td>
</tr>
<tr>
<td></td>
<td>– no nicotine self-administration.</td>
</tr>
<tr>
<td></td>
<td>– less somatic signs associated with nicotine withdrawal.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Evidences from mice modify genetically</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CB2−/− mice showed: higher sensitivity to the cocaine-induced motor effects [215].</td>
</tr>
</tbody>
</table>

**2. Distribution of endocannabinoid components in the central nervous system**

The endocannabinoid system is widely distributed in the central and peripheral nervous system [17], and also in many other tissues [20], where it regulates brain functions by acting on different cell types and cellular compartments [17,21,22]. This system is integrated by cannabinoïd receptors, endogenous ligands (endocannabinoids) (eCBs) and their synthesizing and degrading enzymes, intracellular signalling pathways as well as transport systems [15–19].

<table>
<thead>
<tr>
<th><strong>2.1. CB1 and CB2 receptors in the central nervous system</strong></th>
</tr>
</thead>
</table>
| The CB1 receptors (CB1R) are the most abundant G protein-coupled receptors in the brain [23]. Their expression in the central nervous system (CNS) is widespread and heterogeneous and have crucial roles in regulating brain function and pathophysiological processes [17,22,24–33]. CB1R are abundant in the basal ganglia (substantia nigra reticulata, globus pallidus, striatum, entopeduncular nucleus), cortex, NAc, cerebellum and hippocampus [23,31,34,35]. CB1R immunoreactivity is greatly reduced in conditional mutant mice lacking CB1R mainly from GABAergic neurons (GABA-CB1-R), but less in conditional mutant mice lacking CB1R mainly from cortical glutamatergic neurons (Glu-CB1-R) with respect to the wild type [25,26,31,36]. Suggesting a predominant localization of CB1R in GABAergic neurons (See Fig. 1). Substantia nigra pars reticulata lacks CB1R immunoreactivity in GABA-CB1-R, and a large decrease in CB1R staining is observed in the GABA-CB1-R hippocampus but not at the glutamatergic commissural/associational synapses in the dentate molecular layer [25,26,31,36]. Furthermore, a conspicuous CB1R staining is detected in the striatum, cortex, olfactory tubercle, amygdala, hippocampus of genetic rescue mice expressing CB1R only in...
dorsal telencephalic glutamatergic neurons (Glu-CB1-RS) and, remarkably, in the dentate molecular layer [22,25,37]. In the rescue mice expressing CB1R only in GABAergic neurons (GABA-CB1-RS), strong CB1R immunoreactivity is revealed in the cortex hippocampus, anterior olfactory nucleus, piriform cortex, globus pallidus, entopeduncular nucleus, amygdala, and substantia nigra, and moderate to strong in the striatum [22].

CB1R expression is very high in inhibitory GABAergic synaptic terminals mostly in cortical and hippocampal cholecystokinin (CCK)-positive GABAergic interneurons [17,26,35,38–41], low in excitatory glutamatergic synapses [22,25,28,37,42,43], and very low in astrocytes [33,44–48]. CB1R also localizes to mitochondria of neurons [49–53] and astrocytes [33]. Scattered CB1R labeling has been detected in resting microglia (Grandes et al., unpublished).

CB1R expression is very high in inhibitory GABAergic synaptic terminals mostly in cortical and hippocampal cholecystokinin (CCK)-positive GABAergic interneurons [17,26,35,38–41], low in excitatory glutamatergic synapses [22,25,28,37,42,43], and very low in astrocytes [33,44–48]. Brain CB1R are mostly localized in axon terminals and pre-terminals away from the presynaptic active zones and are also localized at mitochondria in neurons [49–53] and astrocytes [33]. Thus, CB1R were distributed in GABAergic terminals (~56%), glutamatergic terminals (~12%), astrocytes (~6%), mitochondria (~15%) and in other compartments (~11%) in the hippocampus [32,33], (See Fig. 1).

In contrast, CB2 cannabinoid receptors (CB2R) were initially considered as the peripheral cannabinoid receptor due to its high expression in the rat spleen [54] and leukocyte subpopulation in humans [55]. Also, the first attempts to identify CB2R in CNS under basal conditions failed since it only could be detected under pathological conditions such as in senile plaques in Alzheimer's disease [56], activated microglial cells/macrophages in multiple sclerosis, spinal cord in amyotrophic lateral sclerosis [57] and in the vicinity of tumours [58]. However, this landscape changed dramatically in the last decade, thanks to the findings from the group of Sharkey and colleagues in 2005 [59] revealing that CB2R are expressed in neurons of the brainstem of mice, rats and ferrets under normal conditions. Since then, further studies have contributed to characterize the expression of CB2R in several brain regions including striatum, amygdala, hippocampus and the (VTA) [60–63]. Interestingly, in some of these brain regions CB2R were detected not only in microglia cells [64,65] but also in neurons [63]. Some authors have not found CB2R in the intact CNS [55,66–70], but other studies have reported neuronal CB2R expression in healthy brain [59,62,71–73]. Nevertheless, the presence of CB2R has been described in cortical, hippocampal, pallidal and mesencephalic neurons [74], as well as in the hippocampus, frontal cortex, amygdala and striatum [60,62,73,75–77]. Furthermore, these receptors have also been identified in striatal GABAergic neurons of non-human primates [74,78] as well as in the amygdala, caudate, putamen, NAc, cortex, hippocampus and cerebellum [79,80]. However, the localization of CB2R in the CNS remains controversial since doubts have been raised about the specificity of CB2R antibodies [65,81]. New genetic strategies based on mouse lines expressing enhanced green fluorescent protein under the control of the CB2 promoter have been developed to circumvent this problem [70].

### 2.2. Endocannabinoids in the central nervous system

The eCBs are lipid messengers that exert their influence in a paracrine, autocrine and probably endocrine mode, because their lipid nature allows them to diffuse and cross membranes [15,17,18,80–83]. They are cannabinoid receptor agonists and constitute a family of molecules that are not accumulated in secretory vesicles but rather synthesized on demand and released right after to the extracellular space following physiological and pathological stimuli.

The two main eCBs are derivatives of polyunsaturated fatty acids, N-arachidonoyl ethanolamine (anandamide, AEA) [84] and 2-arachidonoyleglycerol (2-AG), being this last eCB the most abundant in the brain [85]. The AEA precursor N-arachidonoyl phosphatidylethanolamine (NAPE) is generated by the transfer of arachidonic acid from phosphatidylycerine to phosphatidylethanolamine by the Ca2+ dependent N-acyltransferase [83,86,87]. Then, AEA synthesis is produced by the
N-acylphosphatidylethanolamine specific phospholipase D (NAPE-PLD) that hydrolyses N-arachidonoyl phosphatidylethanolamine localized in cell membranes [83,88]. The AEA half-life is very short because of its quick uptake by a high affinity AEA membrane transporter distributed in neurons and glia [89]. AEA is inactivated by fatty acid amide hydrolase (FAAH) present in many organs and also in the brain [83,90,91] at postsynaptic localization [35,83,92]. FAAH is a serine-hydrolase enzyme bound to intracellular membranes that catalyzes AEA into arachidonic acid and ethanolamine [87].

2-AG participates in the CB1R-dependent retrograde signalling and is an intermediate metabolite for lipid synthesis providing arachidonic acid for prostaglandin synthesis [81,83,87]. Neuronal membrane depolarization or the activation of Gq-coupled GPCRs triggers the synthesis of 2-AG [83]. The diacylglycerol precursors come from the hydrolysis of membrane phosphatidylinositol by phospholipase C, β or δ. The degradation of these precursors by DAGL-α and DAGL-β drives 2-AG synthesis [80,81,83,93,94]. The DAGLα isoform synthesizes the greatest amount of 2-AG, whereas DAGLβ synthesizes 2-AG under certain circumstances [89]. Monocacylglycerol lipase (MAGL) is a serine-hydrolase enzyme mainly found in presynaptic terminals that catalyzes 2-AG into arachidonic acid and glycerol [35,81,83,90,91]. Also, the α/β-hydrolase domain 6 (ABHD6) and domain 12 (ABHD12) degrade 2-AG [83,87].

2.3. Functional localization of CB1 and CB2 receptors in the mesocorticolimbic system

The expression of CB1R is medium–high in the dorsal and ventral striatum, and low in the VTA [23,31,95]. Dorso-medial and ventral striatal glutamatergic neurons significantly express CB1R. Indeed, the CB1R distribution in the striatum is maintained in GABA-CB1-KO mice although it is strongly reduced in Glu-CB1-KO [31]. In VTA, CB1R immunoreactivity has been localized to both symmetric synapses of local GABAergic neurons [96–98] and to vesicular glutamate transporter-positive presynaptic terminals apposed to dendrites of DA neurons [99]. CB1R co-localize with tyrosine hydroxylase (TH) demonstrating a direct regulatory role on VTA DA neurons [100]. Moreover, DAGLα is strongly expressed in the VTA neurons in postsynaptic TH-positive and TH-negative dendrites to excitatory and inhibitory synapses [97]. Interestingly, the postsynaptic DAGLα labeling is related to the pre-synaptic localization of CB1R suggesting a link between 2-AG synthesis and CB1R activation in the VTA [35,97], (See Fig. 2).

Fig. 2. Functional localization of CB1R and CB2R in the main structures related to drug addictive properties. In the ventral tegmental area (VTA), CB1R are found in GABAergic neurons and glutamate presynaptic terminals apposed to dendrites of dopaminergic neurons [88]. CB1R may be expressed as well in the VTA DA neurons [89]. Diacylglycerol lipase α (DAGLα) is expressed postsynaptically, in DA and non-DA neurons of the VTA, in presynaptic terminals in the nucleus accumbens (NAc) and in synapses of the prefrontal cortex (PFC), where it co-localizes with metabotropic glutamate receptor 5 (mGlur5) and apposes to presynaptic terminals containing CB1R, suggesting its activation through 2-arachidonoylglycerol (2-AG) [24,86,104]. α/β-hydrolase domain-containing 6 (ABHD6), the enzyme that metabolizes 2-AG, is found in the spines facing CB1R in the PFC [110]. Excitatory projections from the PFC synapse with GABAergic interneurons and dopaminergic neurons in the VTA [105,106]. In the NAc, CB1R are localized in excitatory terminals coming from the PFC and in medium spiny neurons and parvalvum interneurons, but not in the DA terminals. Inhibition of GABA release controls DA outflow [85,123–126]. CB2R have been described in non-dopaminergic and dopaminergic VTA neurons [127–130], where its stimulation induces neuronal inhibition and reduction of DA release in the NAc, associated with diminished drug intake [128–130], CCK+: Cholecystokinin-positive.
The endocannabinoid system plays a central role in modulating DA levels in the CNS [101]. CB1R activation increases DA and decreases GABA in the medial PFC [102] and also increases DA firing of single VTA cells [103,104]. The PFC is a key player in emotional learning plasticity [105] and addictive processes [106] and the endocannabinoid system is closely involved in these physiological functions. CB1R are highly expressed in the medial PFC [35,107,108] that mediates an increase in DA transmission [109,110]. High CB1R expression is found in large CCK-containing basket interneurons [111], whereas parvalbumin and somatostatin-expressing interneurons lack this receptor [112,113], (See Fig. 2). Low but detectable CB1R mRNA levels were revealed in the glutamatergic neurons of many cortical regions [25,114]. CB1R staining is noticeable in the striatum, cortex, PFC and amygdala in Glu-CB1-RS mice [22]. Furthermore, CB1R localization is mostly restricted to layers II/III and V/VI of the prefrontal cortex [115]. Presynaptic CB1R are facing postsynaptic metabotropic glutamate receptor type-5 (mGluRS) in dendritic elements that also contained DAGLα in the PFC [116], (See Fig. 2). This molecular arrangement is responsible for the endocannabinoid long-term depression elicited by prolonged synaptic stimulation of excitatory inputs to layers V/VI [116]. Furthermore, the vast majority of the medial PFC excitatory projections to the VTA are from prefrontal and cortical neurons that make excitatory synapses with GABAergic interneurons and also DA neurons [117,118], However, the infrafimbrial medial PFC only sends about 10% of the PFC excitatory projections to the VTA [118]. Interestingly, the bed nucleus of stria terminalis (BNST) is a relay station of this excitatory input from the infrafimbrial cortex to the VTA DA neurons. The infrafimbrial cortical terminals in the BNST are equipped with CB1R and stimulation of these receptors inhibits the activity of VTA DA cells elicited by activation of the infrafimbrial cortex [119]. As to the enzymes, relatively low NAPE-PLD expression [120] and moderate DGLα and DAGLβ mRNA levels have been detected in cortical regions [121]. On the other hand, FAAH immunoreactivity is observed in neuronal cell bodies and dendrites throughout cortical layers II-VI and in layer V neurons [35,92]. MAGL mRNA is more strikingly detected in layer IV, deep layer V, and in layer VI throughout the cortex [90]. Finally, the ABHD6 immunolocalization in the PFC is mostly in dendritic spines facing CB1R immunopositive terminals [122], (See Fig. 2).

The basolateral amygdala contains abundant CB1R that modulate GABAergic synaptic transmission [123] and excitability [124], and is functionally involved in reward related memories and memory consolidation [125–127]. The CB1R expression is high in CCK-positive GABAergic synaptic terminals in basolateral amygdala [35,128] and low in glutamatergic neurons of cortical origin in this area [25,35,128]. Neurons in the basolateral amygdala exhibit low NAPE-PLD mRNA [120]. DAGLα is at postsynaptic perikaryal membranes of pyramidal neurons receiving CCK-containing aononal boutons immunopositive for CB1R and MAGL [35,128]. Furthermore, CB1R immunoreactive fibers sit around FAAH-immunoreactive neuronal cell bodies [92].

The NAc has also an important role in reinforcing addictive behaviors [129] and contains low to moderate CB1R levels and abundant DA receptors [130–132]. The CB1R are localized in excitatory PFC-NAc synaptic terminals, but not in the DA VTA-NAc, as well as in the GABAergic axon terminals of local medium-spiny neurons and parvalbumin-positive interneurons in the NAc [131,133,134], (See Fig. 2). Inhibition of GABA release by cannabinoids seems to control DA release in NAc [96,135–138]. As expected, DGLα is distributed in dendritic spines and at perisynaptic positions of somatodendritic domains [134], (See Fig. 2), moderate MAGL mRNA is detected in the NAc shell [90], but FAAH does not seem to be present [92].

Finally, the presence of CB2R in DA cell bodies has also been reported [63,139–142]. Hence, CB2R mRNA and protein were detected in TH-immunopositive and TH-immunonegative VTA neurons [63,139–141], (See Fig. 2). Furthermore, CB2R mRNA expression increases in the VTA DA neurons, as well as in the PFC and striatum, after cocaine self-administration. Interestingly, CB2R activation inhibits VTA DA neurons [63,139–141,143] leading to a decrease in DA release in the NAc and, as a consequence, a reduction in cocaine self-administration [141]. Nevertheless, doubts have been raised with regards to the specificity of the antibodies used to detect CB2R by immunohistochemistry techniques [35].

3. Role of CB1 receptors in drug addiction

CB1R and its endogenous ligands are expressed through the mesocorticolumbic pathway and also in the brain regions involved in decision-making, withdrawal symptoms and relapse [106,144]. This distribution makes CB1R essential for the establishment of addiction to cannabinoid drugs, and is also crucial for the neurobehavioral processes triggered by any of the prototypical drugs of abuse.

3.1. Involvement of CB1 receptors in drug rewarding properties

One of the principal substrates of the rewarding effect of drugs of abuse is the mesocorticolumbic pathway, which consists of DA neurons from the ventral tegmental area (VTA) that send projections to the NAc and other areas of the limbic forebrain. In the VTA, glutamatergic and GABAergic terminals synapse with the DA neurons and CB1R are expressed presynaptically to control neurotransmitter release. GABAergic transmission inhibits DA neurons and limits the reward sensation, and presynaptic CB1R in these synapses inhibit GABA release, improving disinhibition and promoting reward. On the contrary, glutamatergic signaling activates DA neurons and induces long-term potentiation associated with the hedonic responses [106]. Thus, in glutamatergic synapses, postsynaptic eCBs act retrogradely on presynaptic CB1R limiting DA release. However, the predominant tone is GABAergic and acute administration of CB1R agonists induces disinhibition and reward, although these effects are highly dose-sensitive and may shift to negative reinforcing effects as doses increase [145]. Through this presynaptic control, CB1R in the VTA modulate the DA efflux in the NAc elicited by cannabinoid drugs, but also the increases in DA observed after other prototypical drugs of abuse such as morphine, nicotine and ethanol [145]. Indeed, genetic and pharmacological blockade of CB1R abolished drug-induced DA increases in rodents treated with Δ9-tetrahydrocannabinol (THC), nicotine, heroin, morphine or ethanol [146–149]. The consequences of CB1R control were demonstrated in animal models of reward showing that CB1R agonists enhance conditioned place preference. Rodents treated with CB1R agonists displayed increased preference for contexts associated with nicotine [150] and ethanol [151,152], although the results obtained with morphine or heroin were contradictory [153]. On the contrary, conditioned place preference experiments in CB1R knockout mice showed a reduction of nicotine place preference [154] and ethanol-associated contexts [155], and mixed results were obtained in morphine-treated mice [153,156]. However, the treatment with the CB1R antagonist rimonabant decreased conditioned place preference for morphine, heroin, ethanol and nicotine, suggesting an effect CB1R on primary reward-associated memories. On the other hand, drug self-administration experiments where animals freely operate a lever to self-administer drug also showed inhibition of this operant behavior when CB1R activity was inhibited, either pharmacologically or genetically. This effect was observed for all the drugs mentioned above, including morphine [157], heroin [158], ethanol [159] and nicotine [147]. Hence, CB1R seem essential for the reinforcing and motivational properties of these drugs of abuse, and are involved in the execution of the operant behavior that promotes its consumption.

Psychostimulant drugs such as cocaine, methamphetamine or MDMA have a different mechanism of action to induce reward, since they produce their effects through direct modulation of monoamine transporters in the DA terminals [160]. Thus, targeting VTA CB1R did not affect the DA release induced by these drugs because they act directly on the NAc terminals [149,155,161,162]. Indeed, mice lacking...
CB1R maintained conditioned place preference induced by cocaine and MDMA [155,162,163]. Other studies showed that treatment with rimonabant impaired conditioned place preference to these psychostimulant drugs, however the doses of psychostimulants were lower than in the studies using knockout mice [164–166], suggesting that high cocaine doses could circumvent the modulatory function of the endocannabinoid system. Studies using drug self-administration paradigms have yielded mixed results in CB1R knockout mice, with attenuation of drug-taking behavior [149,162] or no change in restrained mice [167]. Interestingly, treatment with CB1R agonists decreased self-administration of cocaine [168,169] and MDMA [170], an effect that could be related to a decrease in the dose needed to obtain reward when CB1R agonists are co-administered. Alternatively, CB1R of PFC neurons have shown effect reducing DA outflow in the NAc, which could explain an effect of CB1R constraining reward in certain experimental conditions [171]. Rimonabant treatment lacked effect on operant responding for cocaine under fixed-ratio schedules of reinforcement once drug-taking behavior was established [161,172,173]. However, it decreased self-administration in progressive ratio schedules where mice are required to increase the number or operant responses to obtain new drug doses [147,149], which suggests a role of CB1R in the motivation to obtain the psychostimulant. While the lack of effect on psychostimulant-induced DA release may indicate that CB1R activity is not related to the basic rewarding response to psychostimulants, they seem relevant for the conscious and repetitive operant behavior associated with the motivation of the animal for the drug. This complex activity involves reward and the association of operant behavior with expectations and hedonic or relieving responses, and is favored by a shift from goal-directed to habitual behaviors. Recent studies highlight the participation of CB1R-expressing orbitofrontal neurons in the control of decision-making [174]. CB1R are expressed in these neurons and in the dorsal striatum, an area that receives orbitofrontal projections. There, CB1R activity favors the shift from goal-directed to habitual behaviors, impairing decision-making and facilitating repetitive drug intake [174,175]. Thus, targeting CB1R has been suggested as an efficient strategy to improve decision-making and facilitate goal-directed behaviors.

3.2. Involvement of CB1 receptors in the negative aspects of withdrawal

During drug addiction, somatic signs of withdrawal may appear, accompanied by anxiety, cognitive impairment and a generalized state of negative affect that promote compulsive drug-seeking [176]. Rimonabant precipitated somatic signs of abstinence in morphine-dependent animals and CB1R knockout mice showed attenuation of ethanol and naltrexone-precipitated morphine withdrawal, depicting the reciprocal modulation of the cannabinoid and the opioid systems [177,178]. On the contrary, genetic deletion of CB1R did not modify the somatic manifestations of nicotine withdrawal [154]. Therefore, the participation on physical withdrawal may depend on the specific mechanism of action of the drug.

The involvement of CB1R in affective responses is highlighted in studies showing the enhanced aggressiveness, anxiety and depressive-like behavior of CB1R knockout mice [156,179]. Acute moderate doses of cannabinoids can be either anxiogenic [180] or anxiolytic [181–183], probably depending on the drug and the specific context. Interestingly, CB1R agonists showed anxiolytic-like effects in mice chronically treated with psychostimulants [184] or nicotine [185]. However, repeated treatments and high doses of cannabinoid agonists trigger negative emotionality in humans and animals, which promotes drug consumption [179,186,187]. Furthermore, the effects of stressful-like stimuli promoting ethanol-taking behavior are mediated through CB1R in mice subjected to a model of ethanol dependence [188]. Altogether, CB1R seem to play an important function modulating affective behaviors and could be relevant in the response of addicts individuals to stressful situations [189].

Furthermore, exposure to drugs of abuse involves formation of memories associated to drug reward and to drug withdrawal. These memories are highly relevant for drug and cue-induced reinstatement of drug-taking behavior, and CB1R have shown a prominent participation on extinction of aversive and contextual memory [24,190]. Indeed, mice lacking CB1R showed an improvement of long-term memory associated with an impairment of long-term potentiation in hippocampal synapses [191]. In this context, CB1R agonists facilitated relapse of alcohol, nicotine, heroin and cocaine-seeking behavior in abstinence animals, whereas CB1R antagonists attenuated cue and drug-induced reinstatement [173,192–194]. Thus, a pronounced CB1R activity may inhibit the memory processes associated to drug withdrawal, whereas CB1R antagonists could be effective enhancing these negative memories and limiting drug intake and relapse. NAc, amygdala and PFC seem to modulate these motivational aspects that can drive drug relapse [24,195,196]. Thus, CB1R activity modulates almost every neurobehavioral processes involved in drug addiction, and would represent an appropriate target to limit drug abuse or favor rehabilitation.

3.3. Targeting CB1 receptor for the treatment of drug addiction

The crucial role of CB1R in the addictive properties of all the prototypical drugs of abuse suggests a potential interest of CB1R antagonists for treating drug addiction. Indeed, several clinical trials have demonstrated the effectiveness of the CB1R antagonist rimonabant to obtain smoking cessation [197] and preliminary clinical results suggest the efficacy of this CB1R antagonist for treating alcohol dependence [198]. Interestingly, this efficacy of Rimonabant was dependent on a genetic polymorphism of the dopamine receptor D2 gene (DRD2) [199]. Rimonabant was approved by the European authorities for the treatment of obesity [200], and it was commercialized in Europe and several countries worldwide from 2006 to 2008. However, the incidence of serious psychiatric adverse events, such as anxiety, depression and suicidal ideation, leads to the sudden withdrawal of rimonabant in 2008 [201]. At that moment, all the research programs that were developed by multiple pharmaceutical companies to obtain new CB1R antagonists were immediately stopped excepting a specific clinical trial to treat liver steatosis [202] that did not achieve the final approval for this indication. Among the different reasons for the failure of rimonabant, the inverse agonist properties of this orthosteric antagonist could account for the appearance of these serious psychiatric side effects. The clinical use of a unique elevated dose of rimonabant (20 mg) that has a very long half-life in humans may also favor the incidence of these central side effects. In addition, obese patients exposed to weight loss therapies are particularly sensitive to emotional disorders and this fact was not taken into consideration in the recruitment of patients to be treated with rimonabant.

Several strategies to target CB1R in a different manner than a complete orthosteric antagonism were initiated after rimonabant withdrawal. The development of neutral antagonists devoid of inverse agonism activity was an approach investigated by several research groups [203] without achieving at the present moment any successful compound of interest for the development of novel clinical trials.

CB1R antagonists unable to cross the blood brain barrier were also investigated in order to obtain the peripheral metabolic effects avoiding the psychiatric side effects associated to the blockade of CB1R at the level of the CNS [204]. However, this experimental approach cannot be used for treating drug addiction since central CB1R must be targeted for such therapeutic purpose. Even more, peripheral CB1R blockade did not show the same efficacy than the full antagonists for treating obesity [205]. This represents an additional limitation for successfully achieving this approach since it was not effective in a disease such as obesity where peripheral CB1R should play a much more important role than in drug addiction.

A possible alternative strategy to reduce the activity of CB1R, that is currently investigated, consists in reducing eCBs levels. In this sense,
several inhibitors of DAGL, the enzyme involved in the synthesis of 2-AG, have been developed with the purpose of decreasing the endocannabinoid levels in this lipid that constitutes the most abundant endocannabinoid in the CNS [206]. Also, dietary manipulations to modify the phospholipid precursors responsible of the biosynthesis of endocannabinoids have been proposed to reduce the endocannabinoid tone. Indeed, dietary n-3 polyunsaturated fatty acids have been reported to reduce eCBs levels, although this effect has been mainly reported in peripheral tissues [207].

Novel endogenous allosteric negative modulators of CB1R activity have been recently identified [208]. Indeed, the endogenous pregnenolone has been reported to act as a signaling specific inhibitor of the CB1R, reducing THC-induced ERK1/2 phosphorylation without modifying the effects on the cAMP pathway. Furthermore, CB1R stimulation increases brain pregnenolone levels, which in turn exerts a negative feedback on the activity of the CB1R antagonizing most of the known behavioral and somatic effects of THC. Pregnenolone acts as a signaling specific negative allosteric modulator binding to a site distinct from that occupied by orthosteric ligands. This negative feedback mediated by pregnenolone represents a loop protecting the brain from CB1R over-activation that has open novel therapeutic approaches. This biased allosteric modulation of CB1R provides a novel research strategy to decrease CB1R activity avoiding the classical side effects related to the orthosteric blockade of these receptors. A preliminary clinical study investigated the effects of a pregnenolone treatment on marijuana craving, but the results posted show that both pregnenolone and placebo-treated groups failed to develop craving symptomatology [209]. However, pregnenolone is a precursor of other steroids, which could represent a limitation for its possible therapeutic use. The possibility to develop pregnenolone derivatives unable to generate other active steroids constitutes a promising approach to exert a negative bias modulation of CB1R avoiding the previously reported side effects, which could be of potential interest for treating drug addiction.


The interest of CB1R antagonists/inverse agonists in the pharmacotherapy of substance use disorders has been underlined in the previous sections. The main interest of these ligands relied on preclinical data showing the efficacy of CB1R inverse agonists/antagonists to inhibit drug-taking behavior in operant behavioral models that mimic drug consumption in substance use disorders (Section 3.2). This effect is associated with loss of dopamine efflux and reward in drugs that evoke dopamine release through modulation of VTA DA neurons (morphine, THC, ethanol, nicotine), whereas in psychostimulant drugs the effect is DA-independent and related with blunted motivation for the drug. One additional interest of disrupting CB1R activity is the inhibition of the shift from goal-directed to habitual behaviors [174], a common behavioral pattern during substance use disorders that participates in the loss of control over drug intake [210]. The anorectic effects of CB1R blockade could also be of interest in therapy for tobacco or cocaine cessation, since weight gain causes distress in these cases, facilitating direct rejection of the treatment [211,212]. In spite of the efficacy of rimonabant demonstrated in clinical trials targeting smoking cessation and alcohol dependence [197,198], the important psychiatric adverse effects associated to rimonabant treatment leads to its withdrawal from the market, the loss of interest for these classical orthosteric antagonists, and the research of the novel strategies to modulate CB1R activity exposed in the previous section.

Although CB1R antagonists are currently not available for clinical purposes, several CB1R agonists have been approved by the regulatory agencies in multiple countries including Europe and USA. Indeed, four different cannabinoïd-based medicines have been approved by the European Medicines Agency (EMA) and/or the United States Food and Drug Administration (FDA): Dronabinol (Marinol® and Syndros®), Nabilone (Cesamet® and Canemes®), Nabiximols (Sativex®) [213] and more recently cannabidiol (CBD) (Epidiolex®) (FDA, 2018). Dronabinol is manufactured as oral capsules or oral solution containing synthetic THC and the main indications are nausea and vomiting due to cancer chemotherapy as well as anorexia associated with weight loss in Acquired Immunodeficiency Syndrome patients. Nabilone is formulated in oral capsules containing a synthetic cannabinoid similar to THC and its main indication is nausea and vomiting associated with cancer chemotherapy. Nabiximols is commercialized as an oromucosal spray containing a similar amount of THC and CBD obtained from extracts of Cannabis sativa. The most common indication of nabiximols is the spasticity associated to multiple sclerosis, and several countries have also authorized its use for neuropathic pain in multiple sclerosis patients. The therapeutic effects of Dronabinol, Nabilone and Nabiximols have been related to the activation of CB1R, although the presence of CBD in nabiximols seems to play an important role for improving the effectiveness and minimizing the psychoactive effects of the formulation. CBD has been very recently approved by FDA (25th June 2018) for the treatment of seizures associated with two paediatric rare diseases, Dravet syndrome and Lennox-Gastaut syndrome. However, the mechanisms involved in these CBD therapeutic effect remains to be fully clarified.

Another approach to target the endocannabinoid system avoiding the central side effects is the development of compounds selectively acting on CB2R that are devoid of such undesirable effects and these receptors also seem involved in the addictive properties of various prototypical drugs.

4. Role of CB2 receptors in drug addiction

A great deal of research has been focused in the study of the role of CB2R in the central and peripheral nervous system. The expression of CB2R is located in brain regions belonging to classical neuronal circuits involved in drug addiction, such as the VTA, NAc, amygdala and hippocampus which promotes studies to understand further its potential role in these pathological conditions. In this section, we detailed the growing evidences suggesting that CB2R present a pivotal role in addictive behaviors, including cocaine, ethanol and nicotine addiction.

4.1. Role of CB2 receptors in cocaine addiction

Converging evidences support the involvement of CB2R in different aspects related with cocaine addiction. On the one hand, genetic studies indicated that CB2R play a relevant role in cocaine motor sensitization. Mice overexpressing CB2R in the (CB2xP) displayed less hyperlocomotor effects than the prototypical drugs. Converging evidence support the involvement of CB2R in drug addiction, both systemic and locally into the NAc, of the selective CB2R antagonist JWH133 blocked cocaine hyperlocomotion in mice [143]. Interestingly, this effect was observed in CB2−/− knockout mice but disappeared in CB2+/− mice, demonstrating the involvement of CB2R in these effects of JWH133 [143]. However, in another study [216] the administration of the cannabinoid CB2R antagonist, AM630, failed to modify the locomotor effects induced by acute or repeated administration of cocaine in rats. Even so, AM630 reversed the cocaine-induced alterations in cell proliferation including neurogenic, apoptotic and gliosis processes [216].

Besides, CB2R appear to be involved in the reinforcing properties of cocaine since cocaine induced place aversion instead of place preference in CB2xP mice, and these transgenic mice present an impairment in the acquisition of cocaine self-administration [214]. Conversely, intranasal or intra-acccumbens local administration of JWH133 inhibited intravenous cocaine self-administration [143]. In addition,
the administration of the cannabinoid CB2R antagonist SR144528 before the priming doses of cocaine significantly reduced the reinstatement of cocaine seeking behavior in mice [217]. In contrast, the blockade of CB2R did not modify contextual memories associated with cocaine seeking in which CB1R appear to play a relevant role [217]. Additional research also supports the involvement of CB2R in cocaine addiction. Thus, repeated administration of cocaine significantly increased CB2R gene expression in mouse brain preparations [76]. Besides, in vivo studies demonstrated that repeated cocaine administered reduced CB2R protein expression in the PFC of Sprague-Dawley rats only during adolescence (PND33-39) without any alteration in the hippocampus nor in any brain region analyzed in the adulthood [218]. On the contrary, CB2R immunoreactivity decreased in Lewis and Fischer 344 rats exposed to cocaine self-administration [219]. The differences between these studies may be due to (1) the strain of rats used (Sprague-Dawley, Lewis and Fischer 344), (2) the doses and the pattern of cocaine administration, (3) the technique used (western blot vs immunohistochemistry), and (4) the time elapsed between cocaine exposure and samples collection (25 days vs 24 h after the last self-administration session).

All these data support the fact that CB2R modulate cocaine reward, seeking behavior and locomotor-stimulating effects. However, future studies are necessary to further explore the exact role of CB2R in the different aspects of cocaine addiction

4.2. Role of CB2 receptors in alcohol addiction

Several studies revealed the implication of CB2R in the modulation of alcohol consumption and reward. Up to date, two studies were carried out to evaluate the response of CB2−/− mice under different models of alcohol consumption. A first study demonstrated that CB2−/− mice showed high vulnerability to the pharmacological effects of single doses of ethanol [220]. It was also demonstrated that CB2−/− mice presented increased voluntary ethanol consumption in the two-bottle paradigm and motivation to drink in the oral ethanol self-administration [220]. Accordingly, the administration of the cannabinoid CB2R-agonist beta-caryophyllene reduced ethanol conditioned place preference and ethanol consumption in mice [221]. Interestingly a significant incidence of the single nucleotide polymorphism in the CNR2 gene locus, R63Q, was found, in a cohort of Japanese alcoholic patients [222]. This single nucleotide polymorphism leads to a missense mutation in the first intracellular domain, resulting in a decreased cellular response to ligands of CB2R.

More recently, a potential close relationship has been reported between CB2R, stress and alcohol consumption [223]. Indeed, CB2R seems necessary to deal with stress situations that significantly increase ethanol intake. In line with this, previous studies reported that CB2xP mice presented reduced anxiety-like behavior and modified reaction to stress, also supporting an involvement of CB2R in the regulation of stress responses [61]. Moreover, sub-chronic administration of the cannabinoid CB2R-agonist JWH015 increased alcohol consumption only in mice previously exposed to chronic stress without any effect under non-stressed conditions [222]. Consistent with these results, a downregulation of CB2R, CB1R and MAGL has been detected in the amygdala [224] and striatum [225] of rats exposed to repeated ethanol withdrawal.

Altogether, these results establish an important starting point for follow-up basic and clinical studies to clarify the therapeutic utility of CB2R pharmacological modulation in alcohol dependence.

4.3. Role of CB2 receptors in nicotine addiction

Only few studies have evaluated the role of CB2R in nicotine addiction. Genetic studies revealed that the absence of CB2R attenuated the rewarding effects of nicotine in the conditioned place preference and nicotine reinforcing effects in the self-administration paradigm in mice [226]. Besides, CB2R appear to play a significant role in nicotine withdrawal syndrome since CB2−/− mice showed less somatic signs associated with this withdrawal [226]. However, controversial results were obtained in pharmacological studies. The pharmacological blockade of CB2R by the selective antagonist AM630 decreased nicotine rewarding effects as previously described in CB2−/− mice [226]. On the contrary, AM630 did not modify nicotine self-administration and reinstatement of nicotine seeking in rats [227]. These discrepancies may be due, to: (1) the species of animals (rats vs mice), (2) the different experimental conditions for nicotine self-administration and (3) the doses of AM630 employed. Interestingly, the CB2R receptor agonist O-1966 given in combination with nicotine induced conditioned place preference [228].

Future studies will allow elucidating most of the relevant questions that are still unanswered about the role of CB2R in nicotine addictive properties.

4.4. Mechanisms underlying the modulatory effects of CB2R on drug addiction

Many efforts have been made to clarify the neurobiological mechanisms by which CB2R could display its effects on drug-addiction. Most of the evidences obtained support a close interaction between CB2R and DA system, one of the main modulators of drug-reward. Indeed, the pharmacological and genetic manipulation of CB2R modify key elements of DA system including DA extracellular levels, DA receptors and the synthesizing enzyme TH. Opposite effects on DA extracellular levels in the NAc were observed after the pharmacological activation or blockade of CB2R [143]. While CB2R activation reduced the enhancement of extracellular DA levels in the NAc induced by cocaine, the blockade of CB2R elevated basal extracellular DA levels in the NAc. On the contrary, genetic studies did not reveal any significant difference in the extracellular levels of DA in the NAc between CB2xP and their corresponding wild type controls [214]. It is important to take into account that wild-type mice treated with CB2R agonists are not necessarily equivalent to CB2xP from the behavioral and neurochemical point of view [214].

Although CB2R were found in neurons expressing DA D2 receptors (D2R) in the NAc and VTA [214], future studies are needed to determine a possible functional cooperation between the CB2R and D2R. In support of this hypothesis, endocannabinoids have been reported to modify DA modulation of excitatory currents in the striatum controlled by the expression of D1R or D2R [229], suggesting that activation of postsynaptic DA receptors controls endocannabinoid mobilization. Interestingly, confocal microscopy images revealed that CB2R localized with key targets of nicotine addiction, the nicotine acetylcholine receptors containing alpha-3 and alpha-4 subunits (a3- and a4-nAChRs) [230,231].

Finally, alterations in key elements of the DA system as well as in opioid and nicotine receptors were observed in mice with genetic modifications of CB2R. CB2−/− mice presented reduced TH and mu opioid receptor gene expression in the VTA and NAc, respectively [220,226]. Also, CB2−/− mice presented reduced a3- and a4-nAChRs gene expression levels in the VTA [226]. Interestingly, CB2xP mice presented higher TH and DA reuptake transporter gene expression in the VTA and lower mu opioid receptor gene expression in NAc [214].

These data encouraged the development of future studies to further deepening in the neurobiological mechanisms underpinning CB2R role in brain reward circuits.


Although CB1R activation has been proposed as the main key target for drug addiction, CB2R also appear to play an important role in certain properties of cannabinoids (for review [223]) and could certainly represent an interesting target to develop novel pharmacological
strategies to optimize the therapeutic effects and minimize the occurrence of adverse events of cannabinoid therapy. One of that promising strategy is the use of drugs acting directly over CB2R without activating CB1R. As we described here, the direct modulation of CB2R with agonists or antagonists significantly modified different aspects involved in drug addiction. Pharmacological modulation of CB2R also displayed anxiolytic [233] and antidepressant-like effects [61] along with anti-inflammatory [234–236] and neuroprotective [237] properties that would be of interest for the treatment of substance use disorders. However, none of the synthetic CB2R agonists available to date reached an advanced phase of clinical development. Besides, these drugs presented a narrow therapeutic range above which were also able to activate CB1R [232]. In this respect, CB2R allosteric modulators, able to modulate CB2R function by interacting with allosteric sites, may result promising therapeutic tools. Due to that, these compounds provide a greater subtype selectivity [238]. Another important advantage of allosteric modulators could represent an important advance for the clinical development of cannabinoid therapy.

5. Concluding remarks

Multiple studies have recognized the crucial role of the endocannabinoid system in the neurobiological substrate underlying drug addiction. Early studies have identified the important role of CB1R in modulating the rewarding effects of all the prototypical drugs of abuse underlying the potential interest of this particular target of the endocannabinoid system to develop new approaches for treating drug addiction. However, the serious psychiatric adverse events associated to the blockade of CB1R in the CNS lead to prompt withdrawal from the market of rimonabant, the unique CB1R antagonist commercialized. In spite of this failure of rimonabant, the CB1R still represents an excellent target for the development of novel compounds for treating drug addiction, although other strategies different to the development of complete orthosteric antagonists have been now undertaken. The recent development of allosteric signaling-specific negative modulators of CB1R provides a promising research strategy to decrease CB1R activity avoiding the classical side effects related to the orthosteric antagonists. Recent findings revealing a potential role of CB2R in the addictive properties of different drugs of abuse have also open an interesting research opportunity to develop novel possible therapeutic approaches, including CB2R allosteric modulators. The endocannabinoid system certainly constitutes an excellent source of new possible therapeutic targets for multiple diseases including drug addiction. The initial failure on the development of CB1R antagonists should not discourage the public and private laboratories to continuous research in this promising topic in order to identify the most appropriate way to target the endocannabinoid system for treating CNS disorders.

Acknowledgements

We acknowledge the financial support of the Spanish MINECO (#SAF2017-84060-R-AEI/FEDER-UE), Instituto de Salud Carlos III-RETICS (#RD16/0017/0020), Ministerio de Sanidad, Servicios Sociales e Igualdad-Plan Nacionalobre Drogas (#PNSD-2017I068), Instituto de Salud Carlos III (RD12/0028/0019, RD16/0017/0014 and RD06/0001/1004), Plan Nacional Sobre Drogas (PNSD 2016/016 and 2007/061), Ministerio de Economía y Competitividad (FIS, PI14/00348) and Ministerio de Ciencia e Innovación (SAF2008-01106) to JM.

Financial disclosures

None of the authors reported biomedical financial interests or potential conflicts of interest.

References

[25] K. Monory, F. Massa, M. Egerová, M. Eder, H. Blaudszuen, R. Westenbroek,


preference and increased striatal dopamine D2 receptors, Neuropsychopharmacology 30 (2005) 339–349, https://doi.org/10.1038/sj.npp.1300568.


176 J.T. De Vries, Y. Shabam, J.R. Homberg, H. Crombag, K. Schuurman, J. Dieben, L.J. Vanderschuren, A.N. Schoffelen, A cannabinoid mechanism in replac...